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Abstract: We describe two water-soluble ruthenium com-
plexes, [1]Cl2 and [2]Cl2, that photodissociate to release
a cytotoxic nicotinamide phosphoribosyltransferase
(NAMPT) inhibitor with a low dose (21 J cm@2) of red light
in an oxygen-independent manner. Using a specific NAMPT
activity assay, up to an 18-fold increase in inhibition potency
was measured upon red-light activation of [2]Cl2, while [1]Cl2
was thermally unstable. For the first time, the dark and red-
light-induced cytotoxicity of these photocaged compounds
could be tested under hypoxia (1 % O2). In skin (A431) and
lung (A549) cancer cells, a 3- to 4-fold increase in cytotoxicity
was found upon red-light irradiation for [2]Cl2, whether the
cells were cultured and irradiated with 1% or 21% O2. These
results demonstrate the potential of photoactivated chemo-
therapy for hypoxic cancer cells, in which classical photo-
dynamic therapy, which relies on oxygen activation, is poorly
efficient.
NAMPT is a key enzyme in the salvage pathway of NAD+
biosynthesis, and is abnormally up regulated in cancer cells.[1]
Importantly, high NAMPT expression has been associated
with poor prognosis in different types of cancer, which makes
NAMPT a potential therapeutic target.[2] It has been shown
that NAMPT inhibition leads to a reduction in NAD+
intracellular levels, which can induce apoptosis in cancer
cells.[2a,3] However, it has also been reported that targeting of
NAMPT might lead to side effects such as blindness.[4] A
strategy called PhotoActivated ChemoTherapy (PACT)
might solve selectivity issues.[5] PACT consists of masking
the toxicity of a drug with a caging agent that is released upon
light irradiation, together with the free drug.[5b,6] Ruthenium
polypyridyl complexes are particularly promising photocag-
ing groups since they can be removed using visible light,[7]
whereas most organic caging groups require UV light for
activation.[8] Unlike photodynamic therapy (PDT), a clinically
approved therapeutic approach that relies on the photo-
catalytic activation of 3O2 into
1O2 by a photosensitizer,
[9]
PACT is oxygen-independent,[5b, 9] which makes it a promising
and complementary therapeutic strategy for addressing
hypoxic tumours. However, proof of efficacy of PACT under
hypoxia is still lacking.
Herein, we describe a setup using monochromatic red
light on living cells under hypoxia (1%) for studying the
PACT compounds [1]Cl2 and [2]Cl2 (Scheme 1). Red light is
superior to previously reported blue- or green-light activation
of PACT compounds owing to its deeper tissue penetration
(0.5–1.0 cm),[10] and can be used with higher doses without
significant light-induced cytotoxicity.[11] Two sterically hin-
dered ruthenium photocaging scaffolds were chosen based
upon earlier work by the group of Turro and Kodanko:[12]
[Ru(tpy)(dmbpy)(L)]2+ (tpy = 2,2’;6’-2’’-terpyridine;
dmbpy = 6,6’-dimethyl-2,2’-bipyridine) and [Ru(tpy)(biq)-
(L)]2+ (biq = 2,2’-biquinoline). Both types of complexes
have an absorption band that extends into the red region of
the spectrum,[13] and they photodissociate when the mono-
dentate ligand (L) is a thioether or a pyridine moiety.[12a,14]
These scaffolds were conjugated to 4-[({[4-(2-methyl-2-prop-
anyl)phenyl]sulfonyl}amino)methyl]-N-(3-pyridinyl)benza-
mide (STF-31), a known cytotoxic organic compound con-
taining a pyridine moiety that can coordinate to ruthenium.
The toxicity of STF-31 was reported to originate from
inhibition of both NAMPT[15] and GLUT1.[16] We synthesized
the two STF-31-containing compounds [1]Cl2 and [2]Cl2
(Scheme 1), demonstrated that red light can uncage STF-31,
and show that this leads to efficient PACT under both
normoxia (21% O2) and hypoxia (1 % O2).
Scheme 1. Caged STF-31 compounds [1]Cl2 and [2]Cl2.
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Compounds [1]Cl2 and [2]Cl2 were synthesized by reacting
STF-31 with the precursors [Ru(tpy)(dmbpy)(Cl)]Cl[14] and
[Ru(tpy)(biq)(Cl)]Cl, respectively (Scheme S1 in the Sup-
porting Information). Compounds were isolated as PF6 salts,
purified over Sephadex LH-20, and converted into their
chloride salt by salt metathesis to afford [1]Cl2 and [2]Cl2 as
red or purple solids in 50 % and 44 % yield, respectively.
One of the challenges in PACT is to find the ideal balance
between thermal stability and photoactivation efficiency,
expressed as the photosubstitution quantum yield (F).
Previous research had shown that [Ru(tpy)(dmbpy)(SRR’)]2+
complexes are less stable and more photoreactive than
[Ru(tpy)(biq)(SRR’)]2+ in water,[14, 17] thus preventing their
application in PACT.[18] In contrast, Turro et al. have demon-
strated that complexes with L = pyridine are stable enough to
be isolated while retaining photosubstitution properties under
low-energy visible light (lirr> 590 nm).
[12b, 19] Here, the photo-
reactivity of [1]Cl2 and [2]Cl2 in water was tested under red-
light irradiation. Figure 1 shows the evolution of the elec-
tronic absorption spectrum of [1]2+ upon activation at 625 nm
under deoxygenated conditions in H2O. The initial metal-to-
ligand charge transfer (1MLCT) band at 473 nm was gradually
replaced by a new 1MLCT band at l = 484 nm with a clear
isosbestic point at 477 nm, which indicates the formation of
[Ru(tpy)(dmbpy)(H2O)]
2+ (m/z found 536.1, calc m/z 536.1
for [Ru(tpy)(dmbpy)(OH)]+). In the 1H NMR spectra (Fig-
ure S2), under white-light irradiation in D2O, the doublet for
[1]Cl2 at 6.89 ppm was replaced by two doublets at 6.80 and
7.78 ppm, while the characteristic tBu singlet at 0.94 ppm
disappeared, thus confirming photodissociation of STF-31.
The photosubstitution quantum yields (F625) of 0.058 at RT
and 0.080 at 37 8C are consistent with thermal promotion of
the triplet metal-centred states (3MC) from the photochemi-
cally generated 3MLCT states.[12b] For [2]Cl2, irradiation at
625 nm resulted in a shift of the MLCT band at 531 nm to
549 nm, and an aqua photoproduct [Ru(tpy)(biq)(H2O)]
2+
(found m/z = 607.8, calcd m/z = 608.1 for [Ru(tpy)(biq)-
(OH)]+). The final spectrum for 1H NMR in D2O (Figure S3)
showed a new, distinctive quartet at 8.86 ppm, and a decrease
in the doublet at 6.69 ppm and singlet at 0.90 ppm. Photo-
substitution occurred with a quantum yield F625 of 0.013 and
0.019 at RT and 37 8C, respectively (Table 1). The lower
photoreactivity of [2]Cl2 compared to [1]Cl2 is consistent with
previous work.[12b] Both [1]Cl2 (log P =@0.63: 0.04) and
[2]Cl2 (log P =@0.08: 0.04, see the Supporting Information)
are water-soluble, but STF-31 is not (log P =+ 3.92), thus
resulting in ligand precipitation during photosubstitution of
STF-31 in the NMR tube. Hence the caging Ru complexes
significantly increase the water solubility of the inhibitor.
Before testing these compounds in cancer cells, the dose of
red light necessary to obtain full activation in the cell
irradiation setup was evaluated to be 20.6 J cm@2, which
corresponds to 10 minutes irradiation under normoxia (Fig-
ure S4).[11]
The cytotoxicity of STF-31 and of its caged analogues
[1]Cl2 and [2]Cl2 was first tested in normoxic conditions (21%
O2) against three human cancer cell lines (A549, MCF-7, and
A431) and a non-cancerous cell-line (MRC-5).[11] 24 h after
seeding, the cells were treated with STF-31, [1]Cl2, or [2]Cl2,
and after 6 hours incubation, one plate was irradiated with red
light (628 nm, 20.6 J cm@2) while the other was left in the dark.
At t = 48 h, medium was replaced. Cell viability was then
assayed by using sulforhodamine B (SRB) 96 h after seed-
ing.[21] Half maximal effective concentrations (EC50) for cell
growth inhibition were calculated from the dose–response
curves of treated vs. non-treated wells (Figure 2 and Table S1
in the Supporting Information).
Table 1: Absorption maxima (lmax)and molar absorption coefficients at
lmax (e) and at 625 nm (e625); photosubstitution quantum yields (F625) at
298 and 310 K; 1O2 generation quantum yields (F
D) at 293 K; and
photosubstitution reactivity (x =F625 x e625).
Complex lmax in nm
[a]























[a] In H2O. [b] In CD3OD.
Figure 1. Electronic absorption spectra of [1]Cl2 (left) and [2]Cl2 (right) in deoxygenated H2O under red-light irradiation (625 nm, photon flux
1.30 W 10@7 mols@1). tirr = 5 min (every 30 s), T = 298 K.
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Under normoxia (Figure 2a), STF-31 was highly cytotoxic
in all of the cell lines, including MRC-5. [1]Cl2 also showed
substantial cytotoxicity in all of the cancerous cell lines, but its
effect was limited in the non-cancerous MRC-5 cell line
(EC50> 20 mm). Importantly, a negligible difference was
found between the irradiated and non-irradiated wells. This
result was in great contrast to [2]Cl2, which was less cytotoxic
against the non-cancerous MRC-5 cells in the dark (EC50>
40 mm) and highly toxic (EC50< 10 mm) to cancerous cells
after irradiation, with a marked difference in cytotoxicity
between dark and irradiated cells for both A549 and A431
cells. Considering the minimal 1O2 production efficiency
(0.036, Table 1), this effect is most likely attributed to the anti-
proliferative effect of the photoreleased STF-31.
To validate this hypothesis, [1]Cl2, [2]Cl2, and SFT-31 were
tested under hypoxia, in which 1O2 generation is impaired. We
therefore modified our published LED-based irradiation
setup[11] to allow irradiation of living cells while controlling
the O2 concentration (1.0–21%, Figure S7). We then repeated
the cytotoxicity assay using the same protocol and light dose
of 20.6 Jcm@2, but now at 1.0 % O2 (see Figure S7, lower left).
As shown in Figure 2 and Table S1, the EC50 values for all of
the compounds were found to be higher than under normoxia,
which is consistent with earlier reports on the higher
resistance of hypoxic cells to chemotherapy.[22] No photo-
cytotoxicity was observed for [1]Cl2. However, the photo-
indices found for [2]Cl2 under hypoxia (3.6 and 2.4 for A431
and A549) were identical to those found under normoxic
conditions (3.3 and 2.6 for A431 and A549), thus demon-
strating for the first time that a lower O2 concentration does
not affect the photoindex of the PACT compound [2]Cl2.
We then investigated the enzyme-inhibition properties of
STF-31, which is a reported GLUT-1 and NAMPT inhib-
itor.[15a, 16a,23] When GLUT-1-overexpressing A549 cells[24]
were starved using glucose-free medium, incubated for 2 h
with a vehicle control (2% DMSO), 50 mm STF-31, or 100 mm
phloretin (a well-known GLUT-1 inhibitor),[25] and then
treated with the fluorescent d-glucose analogue NBDG,[26]
and analysed by flow cytometry (Figure S10), STF-31 showed
minimal glucose uptake inhibition compared to phloretin.[27]
Thus, the cytotoxicity of STF-31 is most likely not related to
impaired glucose uptake and GLUT-1 inhibition.
The inhibitory effect of STF-31, [1]Cl2, and [2]Cl2 on
NAMPT activity was then measured in recombinant NAMPT
using the commercial Cyclex assay (Figure 3b). At 2 mm
concentration, STF-31 showed the largest effect on NAMPT
activity, thus confirming that it is a NAMPT inhibitor.[15a]
[2]Cl2 produced a dramatic reduction in NAMPTactivity after
red-light activation, whereas the non-irradiated sample
showed much lower inhibition. A similar effect was observed
for [1]Cl2, although the dark activity was found to be much
higher than for [2]Cl2. The dark half maximal inhibitory
concentrations (IC50) of 4.8 mm for [2]Cl2 was lowered by
a factor of 18 down to 0.26 mm after irradiation, which is
similar to the value obtained for STF-31 (0.25 mm, Table 2).
The NAMPT inhibitory effect of STF-31 was thus fully
recovered upon red-light activation of [2]Cl2.
The almost identical EC50 found for [1]Cl2 in the dark and
after light irradiation, and its high NAMPT inhibition in the
dark, suggest that [1]Cl is thermally unstable: When followed
for 48 hours at 37 8C in the dark in OptiMEM medium
(Figure S8), [1]2+ slowly decomposed to [Ru(tpy)(dmbpy)-
(OH2)]
2+ while [2]2+ remained stable (Figure 4 and Fig-
Figure 2. a) (Photo)cytotoxicity (EC50) in mm for [1]Cl2 and [2]Cl2 in
human cancer cells under normoxia and hypoxia. b) EC50 for STF-31
and cisplatin under normoxia and hypoxia (dark). Data points are
averages (n =3) with 95 % confidence intervals (in mm). * =p,0.05,
** ,0.01, *** ,0.001. Also see Table S1.
Figure 3. a) Normalized mean fluorescence intensity (MFI) of NBDG
in A549 cells treated with control, STF-31, or phloretin. Data points are
averages (n =3) :SD. * =p ,0.05, ** ,0.01, *** ,0.001. b) % of
NAMPT activity observed for compounds vs. control (2 % DMSO) after
1 h. Data points are averages (n =2) with :SEM. *= Vehicle control,
^= [2]Cl2 dark (2 mm), ~= [1]Cl2 dark (2 mm), ^= [2]Cl2 light (2 mm),
~= [1]Cl2 light (2 mm), &= STF-31 (2 mm), != FK866 (20 mm).
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ure S9). This result is in contrast to Kodanko et al. , who used
[Ru(tpy)(dmbpy)]2+ to cage a steroidal CYP17A1 inhibi-
tor.[12a] According to our results, [Ru(tpy)(NN)(L)]2+ com-
plexes are only stable enough for PACTwhen NN = biq, while
complexes with NN = dmbpy are more photoreactive and are
also unstable in the dark.[14]
In conclusion, we have demonstrated for the first time the
potential of PACT in hypoxic cancer cells using a photocaged
NAMPT inhibitor. Whereas under hypoxic conditions, clas-
sical type II PDT would not be effective because of the
absence of oxygen, [2]Cl2 represents a promising form of
photocaged drug, with a similar photoindex under hypoxia
(1% O2) compared to normoxia (21 % O2). Also, this
compound is soluble in water and activated using red light,
whereas most PACT compounds reported to date require UV,
blue or green light for activation. The steric hindrance of
[2]Cl2 is high enough to obtain activation using clinically
relevant red-light doses (21 J cm@2),[28] but low enough to
maintain thermal stability. In contrast, [1]Cl2 is too labile in
the dark, which make it unsuitable for PACT. Altogether this
study represents the first example of PACT where the
phototoxicity index measured in hypoxic cancer cells with
red light can be explained by a low 1O2 quantum yield, an
efficient oxygen-independent photosubstitution reaction, and
enzyme inhibition.
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